These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22047770)

  • 1. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
    Hendrickson AE; Oberg AL; Glaser G; Camoriano JK; Peethambaram PP; Colon-Otero G; Erlichman C; Ivy SP; Kaufmann SH; Karnitz LM; Haluska P
    Gynecol Oncol; 2012 Feb; 124(2):210-5. PubMed ID: 22047770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
    Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
    Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
    Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
    Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Litzow MR; Mesa RA; Hogan W; Steensma DP; Flatten KS; Loegering DA; Schneider PA; Peterson KL; Maurer MJ; Smith BD; Greer J; Chen Y; Reid JM; Ivy SP; Ames MM; Adjei AA; Erlichman C; Karnitz LM
    Haematologica; 2011 Nov; 96(11):1619-26. PubMed ID: 21791475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer.
    Nogué M; Cirera L; Arcusa A; Batiste-Alentorn E; Balil A; Font A; Perez-Gracia JL; Carrasco EM; Tusquets I
    Anticancer Drugs; 2002 Sep; 13(8):839-45. PubMed ID: 12394269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
    Pedersen KS; Kim GP; Foster NR; Wang-Gillam A; Erlichman C; McWilliams RR
    Invest New Drugs; 2015 Aug; 33(4):963-8. PubMed ID: 25952464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
    Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
    Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
    Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
    Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
    Goff BA; Holmberg LA; Veljovich D; Kurland BF;
    Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
    Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
    Peng P; Shen K; Yang JX; Wu M; Huang HF; Pan LY; Lang JH
    Chin Med Sci J; 2007 Sep; 22(3):177-82. PubMed ID: 17966166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
    Richardson PG; Chanan-Khan AA; Alsina M; Albitar M; Berman D; Messina M; Mitsiades CS; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):438-45. PubMed ID: 20618337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.